Physician profile
John R Cooper
NPI 1417023763
$5,311.77
in general payments reported to CMS, 2019-2025
34 companies · $815 in 2025
The $815 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $548 · 2020: $556 · 2021: $809 · 2022: $755 · 2023: $993 · 2024: $836 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,643.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $890.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $859.44 | 2021-2025 | Vraylar |
| Abbott Laboratories | $627.84 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $484.50 | 2020-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $404.90 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $277.23 | 2019-2025 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $223.44 | 2019-2025 | Farxiga, Airsupra |
| Astellas Pharma US INC | $183.52 | 2019-2023 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.62 | 2019-2024 | |
| Eisai INC. | $153.38 | 2020-2021 | |
| Amgen INC. | $121.22 | 2019-2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $107.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $92.52 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $92.37 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $80.82 | 2024-2025 | Eliquis, Camzyos |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $60.10 | 2020 | |
| Novartis Pharmaceuticals Corporation | $50.41 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $46.44 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.86 | 2023 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $44.15 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $40.81 | 2024-2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.58 | 2025 | Caplyta |
| Almatica Pharma LLC | $30.31 | 2021-2022 | |
| Allergan, INC. | $24.22 | 2019-2020 | |
| Inspire Medical Systems, INC. | $23.69 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $23.09 | 2024 | Gvoke Hypopen |
| Alnylam Pharmaceuticals INC. | $21.81 | 2025 | Givlaari |
| Sanofi-Aventis U.S. LLC | $18.04 | 2022 | |
| Evoke Pharma, INC. | $15.00 | 2020 | |
| Esperion Therapeutics, INC. | $14.60 | 2024 | Nexletol |
| Medtronic Vascular, INC. | $14.32 | 2019 | |
| Aytu Biopharma, INC. | $14.25 | 2020 | |
| Dexcom, INC. | $13.03 | 2021 | |
| Boston Scientific Corporation | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.